Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication

G. Holló, P. Vargha, Péter Kóthy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 ± 3.2 mmHg (mean ± SD) to 17.3 ± 2.6 mmHg at week 12 (p <0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 ± 3.5 mmHg to 17.7 ± 2.4 mmHg (p <0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 ± 2.1 mmHg to 15.7 ± 1.5 mmHg (p <0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 ± 3.4 mmHg to 17.4 ± 2.4 mmHg (p <0.001 ). Defining responders as having an IOP decrease > 2.0 mmHg or ≥ 5 mmHg at week 12, the responder rate was respectively 62.9% or 31% for the total study population; 86.5% or 54.1% when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation.

Original languageEnglish
Article number3143
Pages (from-to)1943-1948
Number of pages6
JournalCurrent Medical Research and Opinion
Volume21
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Open Angle Glaucoma
Intraocular Pressure
Compliance
latanoprost
Hungary
Hyperemia
Patient Compliance
Travoprost
Research Design
Population

Keywords

  • Compliance
  • Intraocular pressure
  • Travoprost

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{43c0a1edb55e49dd8f675cde204c5f6d,
title = "Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication",
abstract = "Objective: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48{\%}) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 ± 3.2 mmHg (mean ± SD) to 17.3 ± 2.6 mmHg at week 12 (p <0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 ± 3.5 mmHg to 17.7 ± 2.4 mmHg (p <0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 ± 2.1 mmHg to 15.7 ± 1.5 mmHg (p <0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 ± 3.4 mmHg to 17.4 ± 2.4 mmHg (p <0.001 ). Defining responders as having an IOP decrease > 2.0 mmHg or ≥ 5 mmHg at week 12, the responder rate was respectively 62.9{\%} or 31{\%} for the total study population; 86.5{\%} or 54.1{\%} when travoprost was added to the established therapy; 54.5{\%} or 24.0{\%} if latanoprost was switched to travoprost; and 90.9{\%} or 36.4{\%} for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation.",
keywords = "Compliance, Intraocular pressure, Travoprost",
author = "G. Holl{\'o} and P. Vargha and P{\'e}ter K{\'o}thy",
year = "2005",
month = "12",
doi = "10.1185/030079905X74916",
language = "English",
volume = "21",
pages = "1943--1948",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication

AU - Holló, G.

AU - Vargha, P.

AU - Kóthy, Péter

PY - 2005/12

Y1 - 2005/12

N2 - Objective: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 ± 3.2 mmHg (mean ± SD) to 17.3 ± 2.6 mmHg at week 12 (p <0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 ± 3.5 mmHg to 17.7 ± 2.4 mmHg (p <0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 ± 2.1 mmHg to 15.7 ± 1.5 mmHg (p <0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 ± 3.4 mmHg to 17.4 ± 2.4 mmHg (p <0.001 ). Defining responders as having an IOP decrease > 2.0 mmHg or ≥ 5 mmHg at week 12, the responder rate was respectively 62.9% or 31% for the total study population; 86.5% or 54.1% when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation.

AB - Objective: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 ± 3.2 mmHg (mean ± SD) to 17.3 ± 2.6 mmHg at week 12 (p <0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 ± 3.5 mmHg to 17.7 ± 2.4 mmHg (p <0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 ± 2.1 mmHg to 15.7 ± 1.5 mmHg (p <0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 ± 3.4 mmHg to 17.4 ± 2.4 mmHg (p <0.001 ). Defining responders as having an IOP decrease > 2.0 mmHg or ≥ 5 mmHg at week 12, the responder rate was respectively 62.9% or 31% for the total study population; 86.5% or 54.1% when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation.

KW - Compliance

KW - Intraocular pressure

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=29144497065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144497065&partnerID=8YFLogxK

U2 - 10.1185/030079905X74916

DO - 10.1185/030079905X74916

M3 - Article

VL - 21

SP - 1943

EP - 1948

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 12

M1 - 3143

ER -